Validation of the Korean Version of the Scale for Outcomes in Parkinson's Disease-Autonomic

ORIGINAL ARTICLE

Ji-Young Kim, In-Uk Song, Seong-Beom Koh, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Jin Whan Cho, Yun Joong Kim, Hyo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeok Lee, Jee-Young Lee, Ji Sun Kim, Ji Young Yun, Hee Jin Kim, Jin Young Hong, Mi-Jung Kim, Jinyoung Youn, Ji Seon Kim, Eung Seok Oh, Hui-Jun Yang, Won Tae Yoon, Sooyeoun You, Kyum-Yil Kwon, Hyung-Eun Park, Su-Yun Lee, Younsoo Kim, Hee-Tae Kim, Joong-Seok Kim

1Department of Neurology, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea
2Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
4Department of Neurology, Kyung Hee University College of Medicine, Seoul, Korea
5Department of Neurology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
6Department of Neurology, Dong-A University College of Medicine, Busan, Korea
7Department of Neurology and Neuroscience Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
8Department of Neurology, Hallym University College of Medicine, Anyang, Korea
9Department of Neurology, Yeungnam University College of Medicine, Daegu, Korea
10Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
11Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
12Department of Neurology, Parkinson/Alzheimer Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
13Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
14Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
15Department of Neurology, College of Medicine, Gachon University, Incheon, Korea
16Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
17Department of Neurology, Ulsan National University Yangsan Hospital, Yangsan, Korea
18Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, College of Medicine, Seoul National University, Seoul, Korea
19Department of Neurology, Chungbuk National University School of Medicine, Chungbuk National University Hospital, Cheongju, Korea
20Department of Neurology, Ewha Womsans University School of Medicine, Ewha Womsans University Mokdong Hospital, Seoul, Korea
21Department of Neurology, Konkuk University Medical Center, Seoul, Korea
22Department of Neurology, Yonsei University Wonju College of Medicine, Wonju, Korea
23Department of Neurology, Bobath Memorial Hospital, Seongnam, Korea
24Department of Neurology, Soochunhyang University Seoul Hospital, Soochunhyang University School of Medicine, Seoul, Korea
25Department of Neurology, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon, Korea
26Department of Neurology, Ulsan University College of Medicine, Ulsan, Korea
27Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
28Department of Neurology, Konkuk University Medical Center, Daegu, Korea
29Department of Neurology, Soochunhyang University Gumi Hospital, Soochunhyang University School of Medicine, Gumi, Korea
30Department of Neurology, Hanyang University College of Medicine, Seoul, Korea

Received: November 24, 2016       Accepted: December 7, 2016
Corresponding author: Joong-Seok Kim, MD, PhD, Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea / Tel: +82-2-2258-6078 / Fax: +82-2-599-9686 / E-mail: neuronet@catholic.ac.kr
*Ji-Young Kim and In-Uk Song contributed equally to this work.
© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Autonomic dysfunctions are commonly observed in Parkinson's disease (PD), and some of these abnormalities are associated with debilitating complications. Some autonomic manifestations appear before the motor symptoms and are more prevalent as the disease progresses. They influence quality of life and treatment modality.

The Scale for Outcomes in Parkinson's disease-Autonomic (SCOPA-AUT) is a patient-reported questionnaire for the focused assessment of autonomic dysfunction in PD. It has been widely translated and validated in PD since its development in 2004 by Visser et al., and is composed of 25 items including five individual aspects: gastrointestinal (GI; 7 items), urinary (6 items), cardiovascular (3 items), thermoregulatory (4 items), pupillomotor (1 item), and sexual (2 items for men and 2 items for women) functions.

There is a lack of reliable questionnaires to assess the full spectrum of autonomic dysfunction in Korean patients with PD. In the present study, we translated the SCOPA-AUT into Korean and assessed the acceptability, reliability and validity of the Korean version of SCOPA-AUT (K-SCOPA-AUT) for use in Korean patients with PD. We also investigated the association between autonomic symptom severities and other Parkinsonian motor, non-motor, and quality of life scores.

### MATERIALS & METHODS

#### Study participants

The Institutional Review Board at each participating hospital approved this study, and written informed consent was obtained from each study subject. The study was conducted as one of validating processes for assessing motor and nonmotor functions (SCOPAs, sleep scales, etc.) in Korean patients with PD by researcher group of Korean Movement Disorder Society.

All subjects were enrolled from 31 movement disorder clinics of university-affiliated hospitals in Korea. The inclusion criteria included consecutive Korean PD patients who met the diagnostic criteria of the United Kingdom Parkinson Disease Society Brain Bank and were on stable doses of anti-Parkinson medications for at least 4 weeks prior to the study. The exclusion criteria were as follows: PD patients who 1) had neurological abnormalities related to atypical PD, 2) had secondary causes of PD such as drugs or structural brain lesions, 3) were taking antipsychotic medications including anti-depressants or...
had a history of psychiatric diseases, or 4) had severe cognitive impairment [Korean version of Mini-Mental State Examination (K-MMSE) < 20].

**Translation**
For the translation of the English version of the SCOPA-AUT into Korean, the following processes were performed: forward translation and backward translation, expert committee review, pretest of the pre-final version and development of the final Korean version.

First, two independent bilingual translators translated the English version of the SCOPA-AUT into Korean, literally. A panel consisting of five authors (SB Koh, JS Kim, TB Ahn, SM Cheon, and SJ Kim) reviewed the translations to confirm a single forward translation. Another bilingual translator translated the Korean version draft of the SCOPA-AUT back into English. Second, discrepancies between the English version of the SCOPA-AUT and the Korean version of the SCOPA-AUT were evaluated by the panel. Third, interviews with four PD patients were conducted to test the interpretation of the translation. Through these processes, the final version of the K-SCOPA-AUT was obtained (Supplementary in the online-only Data Supplement).

**Acceptability, reliability, and validity**
The movement disorder specialists (all authors) conducted the following battery of standard assessment measures: a standard demographic and clinical characteristics form, levodopa equivalent dosage (LED), modified Hoehn and Yahr (H&Y) score, Unified Parkinson’s Disease Rating Scales (UPDRS) parts I, II, and III, K-MMSE, the Korean version of the Montreal Cognitive Assessment (MoCA-K), the Korean version of the Montgomery-Asberg Depression Rating Scale (K-MADRS), the Montreal Cognitive Assessment (MoCA-K), the Korean version of the Parkinson’s Disease Quality of Life 39 (K-PDQ39)

**Table 2** shows the score in each domain and the total score from the K-SCOPA-AUT. The mean total sum of the K-SCOPA-AUT was 12.5 ± 8.2 (mean ± SD) and ranged from 0 to 40. Four patients received a score of 0.

Cronbach’s α-coefficient for the K-SCOPA-AUT was 0.727. All of the K-SCOPA-AUT items showed Cronbach’s α-coefficients of ≥ 0.70 except item 8 (Cronbach’s α-coefficient = 0.695). The correlations between four of the five domains, except the sex-
women domain, and the total K-SCOPA-AUT score were statistically significant [Spearman’s rank correlation coefficient, \( r_S = 0.298–0.641 \), all were \( p < 0.05 \)] (Table 3). The test-retest reliability (The Guttman split half-coefficient) of the total K-SCOPA-AUT was 0.859, and each domain was between 0.666 and 0.906 (Table 3).

The total K-SCOPA-AUT score was 12.5 ± 8.2 (range, 0–40) out of a possible maximum of 69. The total K-SCOPA-AUT score was not related to increasing age and LED; however, it was weakly to moderately associated with motor severity scales (H&Y score, UPDRS part I, II, and III) and moderately to strongly associated with other non-motor symptoms (K-NMSS, K-MADRS) (Table 4). The total K-SCOPA-AUT score was negatively correlated with both the K-MMSE and MoCA-K scores (Table 4). The total K-SCOPA-AUT score was significantly and positively correlated with the PDQ-39 score.

In sub-domain analysis, the GI domain score was especially positively correlated with a wide range of motor and non-motor severity scores (H&Y score, UPDRS, K-NMSS, K-MADRS, and K-PDQ39) (Table 4). The urinary domain and cardiovascular domain scores were also positively related to H&Y score, UPDRS part II, K-NMSS, K-MADRS, and K-PDQ39 (Table 4). The thermoregulatory and pupillomotor domain scores were associated with increasing depression score (K-MADRS). The sex-women domain was not correlated with any of the demographic or disease characteristics data.

**DISCUSSION**

Several researchers have suggested that the most common non-motor symptoms of PD are autonomic and that autonomic dysfunction is correlated with poor health-related quality of life.\(^1\)\(^2\) A scale to evaluate and qualify the severity of autonomic symptoms is very important for the management of PD patients. This specialized scale assessing the full spectrum of autonomic symptoms has been translated and validated in many languages; however, this questionnaire has not yet been validated in Korean. Therefore, we translated the English version of the SCOPA-AUT\(^10\) into Korean and evaluated its reliability and validity for use in Korean patients with PD.

### Table 2. Total and each domain scores of the Korean version of the Scale for Outcomes in Parkinson’s disease-Autonomic (K-SCOPA-AUT)

<table>
<thead>
<tr>
<th>K-SCOPA-AUT domains</th>
<th>Mean ± SD</th>
<th>Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td>2.9 ± 3.0</td>
<td>2 (0–12)</td>
</tr>
<tr>
<td>Urinary</td>
<td>6.3 ± 4.6</td>
<td>5 (0–16)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>1.0 ± 1.4</td>
<td>0 (0–7)</td>
</tr>
<tr>
<td>Thermoregulatory</td>
<td>0.9 ± 1.4</td>
<td>0 (0–6)</td>
</tr>
<tr>
<td>Pupillomotor</td>
<td>0.4 ± 0.8</td>
<td>0 (0–3)</td>
</tr>
<tr>
<td>Sex (men)</td>
<td>0.9 ± 1.7</td>
<td>0 (0–6)</td>
</tr>
<tr>
<td>Sex (women)</td>
<td>0 ± 1.3</td>
<td>0 (0–6)</td>
</tr>
<tr>
<td>Total score</td>
<td>12.5 ± 8.2</td>
<td>11 (0–40)</td>
</tr>
</tbody>
</table>

### Table 3. Test-retest reliability (Gutmann Split Half-coefficient) of the Korean version of the Scale for Outcomes in Parkinson’s disease-Autonomic (K-SCOPA-AUT) domains and correlations between each domain score and the total K-SCOPA-AUT score.

<table>
<thead>
<tr>
<th>K-SCOPA-AUT domains</th>
<th>Gutmann Split Half-coefficient</th>
<th>Spearman’s rank correlation ( r_S )</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td>0.883</td>
<td>0.641</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Urinary</td>
<td>0.797</td>
<td>0.861</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>0.822</td>
<td>0.380</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Thermoregulatory</td>
<td>0.666</td>
<td>0.325</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Pupillomotor</td>
<td>0.720</td>
<td>0.324</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Sex-men</td>
<td>0.906</td>
<td>0.298</td>
<td>0.001</td>
</tr>
<tr>
<td>Sex-women</td>
<td>0.884</td>
<td>0.127</td>
<td>0.243</td>
</tr>
<tr>
<td>Total K-SCOPA-AUT scores</td>
<td>0.859</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Table 4. Correlation between the Korean version of the Scale for Outcomes in Parkinson’s disease-Autonomic (SCOPA-AUT) scores and clinical features

<table>
<thead>
<tr>
<th>SCOPA-AUT domains</th>
<th>Age</th>
<th>Disease duration</th>
<th>LED</th>
<th>H&amp;Y</th>
<th>UPDRS part I</th>
<th>UPDRS part II</th>
<th>UPDRS part III</th>
<th>K-MMSE</th>
<th>K-NMSS</th>
<th>K-MADRS</th>
<th>K-PDQ39</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td>0.133</td>
<td>0.225*</td>
<td>0.233</td>
<td>0.339</td>
<td>0.357*</td>
<td>0.310*</td>
<td>0.153</td>
<td>-0.126</td>
<td>0.414*</td>
<td>0.250*</td>
<td>0.393*</td>
</tr>
<tr>
<td>Urinary</td>
<td>0.112</td>
<td>0.156</td>
<td>0.069</td>
<td>0.220*</td>
<td>0.301*</td>
<td>0.375*</td>
<td>0.143</td>
<td>-0.156</td>
<td>0.621*</td>
<td>0.358*</td>
<td>0.483*</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>-0.072</td>
<td>-0.055</td>
<td>0.026</td>
<td>0.192*</td>
<td>0.161</td>
<td>0.213*</td>
<td>0.141</td>
<td>-0.102</td>
<td>0.234*</td>
<td>0.302*</td>
<td>0.324*</td>
</tr>
<tr>
<td>Thermoregulatory</td>
<td>-0.091</td>
<td>0.148</td>
<td>0.049</td>
<td>0.044</td>
<td>0.091</td>
<td>0.138</td>
<td>0.116</td>
<td>0.003</td>
<td>0.153</td>
<td>0.214*</td>
<td>0.226*</td>
</tr>
<tr>
<td>Pupillomotor</td>
<td>-0.144</td>
<td>0.029</td>
<td>-0.049</td>
<td>-0.002</td>
<td>0.212*</td>
<td>0.133</td>
<td>0.058</td>
<td>0.032</td>
<td>0.154</td>
<td>0.228*</td>
<td>0.154</td>
</tr>
<tr>
<td>Sex-men</td>
<td>-0.285</td>
<td>0.011</td>
<td>0.206*</td>
<td>0.068</td>
<td>0.015</td>
<td>0.185</td>
<td>0.108</td>
<td>0.064</td>
<td>0.096*</td>
<td>-0.036</td>
<td>0.007</td>
</tr>
<tr>
<td>Sex-women</td>
<td>-0.117</td>
<td>0.107</td>
<td>0.020</td>
<td>-0.141</td>
<td>0.052</td>
<td>0.031</td>
<td>-0.121</td>
<td>-0.122</td>
<td>-0.091</td>
<td>-0.11</td>
<td>-0.106</td>
</tr>
<tr>
<td>Total</td>
<td>0.037</td>
<td>0.215*</td>
<td>0.171</td>
<td>0.312*</td>
<td>0.324*</td>
<td>0.446*</td>
<td>0.193*</td>
<td>-0.178*</td>
<td>0.640*</td>
<td>0.387*</td>
<td>0.527*</td>
</tr>
</tbody>
</table>

*^Spearman’s rank correlation test, \( p < 0.05 \); *^Spearman’s rank correlation test, \( p < 0.001 \). H&Y: Hoehn and Yahr stage score, K-MADRS: Korean version of Montgomery-Asberg Depression Rating Scale, K-MMSE: Korean version of Mini-Mental Status Examination, K-NMSS: Korean version of Non-Motor Symptoms Scales, LED: levodopa equivalent dosage, K-PDQ39: Korean version of Parkinson’s Disease Quality of Life 39, UPDRS: Unified Parkinson’s Disease Rating Scale.
The internal consistency and reliability of the K-SCOPA-AUT was 0.727 by Cronbach’s α-coefficient, and the test-retest correlation reliability of the total K-SCOPA-AUT was 0.859 measured by the Guttman Split Half-coefficient, which are both considered to indicate acceptable reliability. However, in the sub-analysis of each item and the domain scores, Cronbach’s α-coefficient of item 8 (0.695) and the Guttman split half-coefficient of the thermoregulatory domain (0.666) lacked an acceptable range.

Previous studies have suggested the existence of correlations between the total SCOPA-AUT score and increasing age,19,20 disease severity,19 disease duration,20 and dopaminergic medication dosage;10,19 however, the correlations were not consistent among the studies. In this study, the total SCOPA-AUT score was not significantly associated with increasing age and levodopa dosage, but it was significantly associated with motor severity scales (H&Y, UPDRS part I, II, and III). The mean total SCOPA-AUT score measured in this study population (12.5 ± 8.2) was lower than the reported scores (> 20) of previous reports.10,20 A possible explanation is that our PD patients had milder disease severity, shorter disease duration and were taking lower doses of levodopa compared with the other studies. Furthermore, a considerable number (32.3%) of drug-naive PD patients were enrolled in this study. Therefore, the SCOPA-AUT results in this study may represent autonomic features of PD patients with mild to moderate severity. As expected, the total SCOPA-AUT score was related to non-motor scales (K-NMSS and K-MADRS) and the quality of life scale (K-PDQ-39).

In the sub-score analysis, the GI domain score was positively correlated with disease duration, LED, and a wide range of motor and non-motor severity scores (H&Y, UPDRS part I, II, III, K-NMSS, and K-MADRS), as well as the quality of life score (K-PDQ39). The urinary domain and cardiovascular domain scores were also positively correlated with H&Y, UPDRS part II, K-NMSS, K-MADRS, and K-PDQ39. The thermoregulatory and pupillomotor domain scores were positively correlated with the depression score (K-MADRS). Sexual items in women were not correlated with any of the demographic, disease severity, other autonomic domain scores or total K-SCOPA-AUT score. A total of 61.9% female patients left the sexual items blank or scored ‘not applicable’ on the sexual items (question 24 and 25), but they all answered properly in the other K-SCOPA-AUT items. This is consistent with other preceding studies.19,20 The discrepancy may be associated with a reluctant attitude about sexual dysfunctions due to ethical and cultural backgrounds, leading patients to withhold this information from a physician. A high rate (29.7%) of missing values or scores of ‘not applicable’ were also found in men for sexual items, which was again consistent with previous studies. The total K-SCOPA-AUT score, the GI domain sub-score, and the urinary domain sub-score were moderately to strongly correlated with the K-NMSS score, which indicated that these scores could be used with the K-NMSS to detect autonomic symptoms in PD patients as well.

In conclusion, the K-SCOPA-AUT is a reliable and valid assessment tool for evaluating the autonomic features of Korean PD patients. Autonomic symptoms severities measured by the K-SCOPA-AUT were associated with many other motor and non-motor impairments and influenced quality of life.

Supplementary Materials

The online-only Data Supplement is available with this article at https://doi.org/10.14802/jmd.16057.

Conflicts of Interest

The authors have no financial conflicts of interest.

Acknowledgements

We thank Prof. Dr. J. J. van Hilten for his permission to translate and use the K-SCOPA-AUT in this research. This work was supported by a grant from Samil Pharm. Co., LTD.

REFERENCES